CHAPTER 60 Diseases of the Fetus
The principal determinants of fetal disease include the fetal genotype and the maternal in utero environment. Variation in environmental factors rather than the fetal genetics plays a more significant role in determining overall fetal well-being, although a genetically abnormal fetus may not thrive as well or survive. The ability to assess a fetus genetically, biochemically, and physically is greatly enhanced through the development of amniocentesis, fetoscopy, chorionic villus sampling, fetal blood sampling, and real-time ultrasonography. These techniques permit the early diagnosis and recognition of many fetal disorders and the development of therapeutic interventions.
Fetuses subjected to abnormal maternal, placental, or fetal conditions that restrain growth are a high-risk group and traditionally classified as having intrauterine growth restriction (IUGR). Small for gestational age (SGA) is used as a synonym for IUGR; however, the terms IUGR and SGA are not synonymous. IUGR represents a deviation from expected growth patterns. The decreased fetal growth associated with IUGR is an adaptation to unfavorable intrauterine conditions that result in permanent alterations in metabolism, growth, and development. IUGR most frequently occurs with a variety of maternal conditions that are associated with preterm delivery. SGA describes an infant whose birth weight is statistically less than the 10th percentile or two standard deviations below the mean birth weight for gestational age. The cause of SGA may be pathologic, as in an infant with IUGR, or nonpathologic, as in an infant who is small but otherwise healthy (Table 60-1).
TABLE 60-1 Etiologies for Intrauterine Growth Restriction and Small for Gestational Age at Birth
MATERNAL FACTORS
Age (young and advanced)
Cigarette smoking
Genetics (short stature, weight)
Illnesses during pregnancy (preeclampsia, severe diabetes, chronic hypertension, connective tissue disease)
Infections (intrauterine)
Lack of good prenatal care
Oligohydramnios
Poor nutrition
Race (African American)
FETAL FACTORS
Chromosomal abnormality and nonchromosomal syndromes
Congenital infections
Inborn errors of metabolism
Multiple gestations
Insulin resistance or reduced insulin or insulin-like growth factor-1 production
MATERNAL MEDICATIONS
Antimetabolites (methotrexate)
Heavy metals (mercury, lead)
Hydantoin
Narcotics (morphine, methadone)
Steroids (prednisone)
Substance and illicit drug use (alcohol, cocaine)
Warfarin
PLACENTAL AND UTERINE ABNORMALITIES
Abruptio placentae
Abnormal implantation
Abnormal placental vessels
Chorioangioma
Circumvallate placenta
Fetal vessel thrombosis
Ischemic villous necrosis
Multiple gestations
True knots in umbilical cord
Villitis (congenital infection)
Only about 50% of IUGR infants are identified before delivery. Measurement and recording of maternal fundal height in conjunction with serial ultrasound assessment of the fetus (growth rate, amniotic fluid volume, malformations, anomalies, and Doppler velocimetry of uterine, placental, and fetal blood flow) can aid detection. When suspected and identified, IUGR and SGA fetuses must be monitored for fetal well-being, and appropriate maternal care needs to be instituted (see Chapter 58).
At birth, infants who are mildly to moderately SGA appear smaller than normal with decreased subcutaneous fat. More severely affected infants may present with a wasted appearance with asymmetrical findings, including larger heads for the size of the body (central nervous system sparing), widened anterior fontanelles, small abdomen, thin arms and legs, decreased subcutaneous fat, dry and redundant skin, decreased muscle mass, and thin (often meconium-stained) umbilical cord. Gestational age is often difficult to assess when based on physical appearance and perceived advanced neurologic maturity. Physical examination should detail the presence of dysmorphic features, abnormal extremities, or gross anomalies that might suggest underlying congenital malformations, chromosomal defects, or exposure to teratogens. Hepatosplenomegaly, jaundice, and skin rashes in addition to ocular disorders, such as chorioretinitis, cataracts, glaucoma, and cloudy cornea, suggest the presence of a congenital infection or inborn error of metabolism. Infants with severe IUGR or SGA, particularly in conjunction with fetal distress, may have problems at birth that include respiratory acidosis, metabolic acidosis, asphyxia, hypoxemia, hypotension, hypoglycemia, polycythemia, meconium aspiration syndrome, and persistent pulmonary hypertension of the newborn.
Management of IUGR and SGA infants is usually symptomatic and supportive. The diagnostic evaluation at birth should be directed at identifying the cause of the IUGR and SGA if possible. The consequences of IUGR and SGA depend on the etiology, severity, and duration of growth retardation. The mortality rates of infants who are severely affected are 5 to 20 times those of infants who are appropriate for gestational age. Postnatal growth and development depend in part on the etiology, the postnatal nutritional intake, and the social environment. Infants who have IUGR and SGA secondary to congenital infection, chromosomal abnormalities, or constitutional syndromes remain small throughout life. Infants who have growth inhibited late in gestation because of uterine constraints, placental insufficiency, or poor nutrition have catch-up growth and approach their inherited growth and development potential under optimal environmental conditions.
Hydrops fetalis is caused by immune and nonimmune conditions. Hydrops fetalis is a fetal clinical condition of excessive fluid accumulation in the skin and one or more other body compartments, including the pleural space, peritoneal cavity, pericardial sac, or placenta with resultant high morbidity and mortality. Hydrops initially was described in association with Rhesus blood group isoimmunization. The use of Rho (D) immune globulin has reduced the incidence of isoimmune fetal hydrops. Concurrently the incidence of nonimmune hydrops has increased as a cause of this severe clinical condition.
Fetal hydrops results from an imbalance of interstitial fluid accumulation and decreased removal of fluid by the capillaries and lymphatic system. Fluid accumulation can be secondary to congestive heart failure, obstructed lymphatic flow, or decreased plasma oncotic pressure (hypoproteinemic states). Edema formation is the final common pathway for many disease processes that affect the fetus, including fetal cardiac, genetic, hematologic, metabolic, infections, or malformation syndromes.
The diagnostic workup of the hydropic fetus should focus on discovering the underlying cause. Maternal findings may include hypertension, anemia, multiple gestation, thickened placenta, and polyhydramnios, whereas fetal findings may include tachycardia, ascites, scalp and body wall edema, and pleural and pericardial effusion. Invasive fetal testing may be indicated. Amniocentesis provides amniotic fluid samples for karyotype, culture, alpha-fetoprotein, and metabolic and enzyme analysis. Percutaneous umbilical cord blood sampling can provide fetal blood for chromosomal analysis and hematologic and metabolic studies and provide a source for intervention (fetal transfusion for profound anemia).
Management depends on the underlying cause and the gestational age of the fetus. Resuscitative efforts at delivery are often required. It is often necessary to remove ascitic fluid from the abdomen or pleural fluid to improve ventilation. Profound anemia necessitates immediate transfusion with packed red blood cells.
The overall mortality for infants with nonimmune hydrops is approximately 50%. If the diagnosis is made before 24 weeks of gestation with subsequent premature delivery, the survival rate is approximately 4% to 6%.